Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 8/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19115639 | 0.81 | SLC22A12 (0.33) | CYP3A4 | |
| SCHEMBL19987518 | 0.81 | ALDH1A1 (0.32) | — | |
| SCHEMBL22488083 | 0.79 | ALDH1A1 (0.33) | NFE2L2CETPCYP19A1 | |
| SCHEMBL20466847 | 0.77 | CYP19A1 (0.37) | NFE2L2CETPSMN1; SMN2CYP19A1 | |
| SCHEMBL18415010 | 0.77 | BRS3 (0.38) | KCNH2HTT | |
| SCHEMBL22601465 | 0.75 | CNR2 (0.38) | — | |
| SCHEMBL25886965 | 0.72 | NFE2L2 (0.41) | NFE2L2FAAHKCNH2CYP3A4CETP | |
| SCHEMBL2609326 | 0.72 | CCR9 (0.40) | NFE2L2RAB9AKMT2ASMN1; SMN2CYP19A1 | |
| SCHEMBL4729458 | 0.72 | TRPV4 (0.37) | CYP3A4 | |
| SCHEMBL29649716 | 0.70 | TRPV4 (0.40) | FAAHKCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167099-A1 | NEW PYRAZINE COMPOUND | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167099-A1 | NEW PYRAZINE COMPOUND | EGFR, ERBB2, WEE1 | NFE2L2 962/4885FAAH 3975/4885KCNH2 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.